NeoGenomics (NEO) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic
July 28, 2020 7:02 AM EDTSecond-Quarter 2020 Results and Highlights:
Consolidated revenue decreased 14% to $87 millionClinical Services revenue decreased 17% to $74 millionPharma Services revenue increased 3% to $13 millionPharma Services backlog increased 63% to $173 millionFinancial position strengthened with $322 million net convertible note and equity offeringsTest menu expanded with suite of solid tumor liquid biopsy testsStrategic collaboration and minority investment in Inivata establishedHigh-capacity COVID-19 testing lab operationalizedFORT MYERS, FL / ACCESSWIRE / July 28, 2020 / NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of... More
